Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Thomas W Flaig

Showing results (11-20 of 142) with videos related to

Pageof 15
Sort By:
Cancer Investigation|August 31, 2006
Mitoxantrone-associated acute myelogenous leukemia in a patient with high-risk adenocarcinoma of the prostate: a case report and brief reviewDaniel W Bowles, Thomas W Flaig
Oncology (Williston Park, N.Y.)|December 18, 2015
Upfront Chemotherapy for Metastatic Prostate CancerElaine T Lam, Thomas W Flaig
F1000Prime Reports|May 27, 2014
Geriatric considerations in the treatment of advanced prostate cancerElizabeth R Kessler, Thomas W Flaig
Oncology (Williston Park, N.Y.)|November 19, 2014
Visceral metastases in prostate cancer: an underestimated and understudied subgroupMaria T Bourlon, Thomas W Flaig
Oncology (Williston Park, N.Y.)|March 8, 2012
Optimizing outcomes of advanced prostate cancer: drug sequencing and novel therapeutic approachesE David Crawford, Thomas W Flaig
Expert Opinion on Pharmacotherapy|October 22, 2008
Management of the side effects of androgen deprivation therapy in men with prostate cancerThomas W Flaig, L Michael Glodé
Nature Reviews. Urology|May 30, 2012
Prostate cancer: celecoxib trampled in the STAMPEDE trialElaine T Lam, Thomas W Flaig
Oncology (Williston Park, N.Y.)|March 1, 2014
Sequencing medical therapy in prostate cancer: not as easy as 1-2-3Elizabeth R Kessler, Thomas W Flaig
Drugs & Aging|November 9, 2012
Optimal management of recurrent prostate cancer in older patientsElizabeth R Kessler, Thomas W Flaig
Bladder Cancer (Amsterdam, Netherlands)|August 15, 2020
Review of SWOG S1314: Lessons from a Randomized Phase II Study of Co-Expression Extrapolation (COXEN) with Neoadjuvant Chemotherapy for Localized, Muscle-Invasive Bladder CancerPeter Boxley, Melissa Plets, Thomas W Flaig
Pageof 15

Showing results (11-20 of 142) with videos related to

Sort By:
Pageof 15
Cancer Investigation|August 31, 2006
Mitoxantrone-associated acute myelogenous leukemia in a patient with high-risk adenocarcinoma of the prostate: a case report and brief reviewDaniel W Bowles, Thomas W Flaig
Oncology (Williston Park, N.Y.)|December 18, 2015
Upfront Chemotherapy for Metastatic Prostate CancerElaine T Lam, Thomas W Flaig
F1000Prime Reports|May 27, 2014
Geriatric considerations in the treatment of advanced prostate cancerElizabeth R Kessler, Thomas W Flaig
Oncology (Williston Park, N.Y.)|November 19, 2014
Visceral metastases in prostate cancer: an underestimated and understudied subgroupMaria T Bourlon, Thomas W Flaig
Oncology (Williston Park, N.Y.)|March 8, 2012
Optimizing outcomes of advanced prostate cancer: drug sequencing and novel therapeutic approachesE David Crawford, Thomas W Flaig
Expert Opinion on Pharmacotherapy|October 22, 2008
Management of the side effects of androgen deprivation therapy in men with prostate cancerThomas W Flaig, L Michael Glodé
Nature Reviews. Urology|May 30, 2012
Prostate cancer: celecoxib trampled in the STAMPEDE trialElaine T Lam, Thomas W Flaig
Oncology (Williston Park, N.Y.)|March 1, 2014
Sequencing medical therapy in prostate cancer: not as easy as 1-2-3Elizabeth R Kessler, Thomas W Flaig
Drugs & Aging|November 9, 2012
Optimal management of recurrent prostate cancer in older patientsElizabeth R Kessler, Thomas W Flaig
Bladder Cancer (Amsterdam, Netherlands)|August 15, 2020
Review of SWOG S1314: Lessons from a Randomized Phase II Study of Co-Expression Extrapolation (COXEN) with Neoadjuvant Chemotherapy for Localized, Muscle-Invasive Bladder CancerPeter Boxley, Melissa Plets, Thomas W Flaig
Pageof 15